Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enalapril + nitrendipine
- Development stage
- Phase 2
- Lead developer
- Trommsdorff
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Eneas is a fixed-dose combination tablet containing the angiotensin-converting enzyme (ACE) inhibitor enalapril maleate (10 mg) and the dihydropyridine calcium channel blocker nitrendipine (20 mg). It is indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled by either agent alone. Enalapril acts as a prodrug that is hydrolyzed to enalaprilat, which inhibits ACE, thereby reducing angiotensin II levels, decreasing vasopressor activity, and lowering aldosterone secretion. Nitrendipine inhibits the influx of extracellular calcium ions through voltage-dependent L-type calcium channels in vascular smooth muscle cells, leading to vasodilation and reduced peripheral vascular resistance. Together, the two components provide synergistic blood pressure-lowering effects. Eneas was originally developed by Grupo Ferrer and is marketed in Germany and other European countries by Trommsdorff (a subsidiary of Dermapharm).
- Brand names
- Eneas
- Other names
- Enalapril maleate + nitrendipineEnalapril maleate/nitrendipineEnalapril/nitrendipineNitrendipine + enalaprilNitrendipine/enalapril
02
Targets
ACE (Angiotensin Converting Enzyme)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)
Beyond the preview
Go deeper on enalapril + nitrendipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enalapril + nitrendipine.